Biotech IPOs slow in Q3 despite improvement in general markets
14 October 2016
Biotech IPOs were sluggish in the third quarter, with only seven companies successfully completing their offerings on U.S. exchanges, raising a collective $396 million in the process, according to BioWorld analysis. That was 42 percent below the 12 biotech IPOs, raising $1.35 billion in the third quarter last year and 36 percent off the 11 companies completing their offerings in the second quarter this year, raising $564 million.
Ganaxolone Reduces Seizures in Females with PCDH19 Pediatric Epilepsy
29 September 2016
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced top-line results from a Phase 2 exploratory open-label clinical trial evaluating ganaxolone, its CNS-selective GABAA modulator, in females with PCDH19 pediatric epilepsy. In the trial, ganaxolone reduced seizure frequency from baseline in the majority of patients enrolled in the study and was generally safe and well tolerated. PCDH19 pediatric epilepsy is a rare, serious epilepsy characterized by early-onset cluster seizures, cognitive and sensory impairment, and behavioral disturbances, with no approved treatments. In 2015, the U.S. Food and Drug Administration granted Orphan Drug Designation to ganaxolone for the treatment of PCDH19.
Two New Corneal Inlays Increase Options for Presbyopia
27 September 2016
Until recently, the go-to options for treating presbyopia were reading glasses, monovision with either a contact lens or laser vision correction, or multifocal intraocular lenses. Today we now have one more arrow in our quiver: the corneal inlay, which offers patients a safe, less invasive, and reversible alternative to laser vision correction and intraocular lenses.
Miramar Labs’ CEO Interviewed on Bloomberg Radio
12 September 2016
Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today that the company’s CEO, Mike Kleine, was interviewed on Bloomberg Radio’s “Taking Stock” on September, 12th, 2016 at 3:15pm EDT.
ReVision Optics Announces First U.S. Commercial Cases of Raindrop® Near Vision Inlay
31 August 2016
ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces the U.S. commercial launch of the Raindrop® Near Vision Inlay. The initial launch plan calls for the company’s direct field force to focus on sites that participated in the U.S. IDE clinical trial, followed by a more broad-based expansion later in 2016.
Miramar Labs, Inc.® Appoints Patrick F. Williams To Board of Directors
30 August 2016
Miramar Labs, Inc., (MRLB), a global aesthetic company, announced today the appointment of Patrick F. Williams to the Company’s Board of Directors. Mr. Williams will serve as Chairman of the Audit Committee, bringing nearly 20 years of financial management experience.
ReVision Optics Secures $10 Million Credit Facility from Square 1 Bank
18 August 2016
ReVision Optics®, Inc. (RVO), a leader in implantable presbyopia-correcting corneal inlay technology, today announced that it has secured a $10 million credit facility from Square 1 Bank, a division of Pacific Western Bank. RVO announced receipt of U.S. Food and Drug Administration (FDA) approval for its Raindrop® Near Vision Inlay for the surgical correction of presbyopia on June 29, 2016. Proceeds from the credit facility will be used for working capital purposes including commercial operations.
15 August 2016
NovaDigm Therapeutics, a company developing innovative immunotherapeutics and preventative vaccines for fungal and bacterial infections, today announced positive data from the Company’s Phase 2a clinical trial evaluating its NDV-3A immunotherapeutic vaccine in women with recurrent vulvovaginal candidiasis (RVVC). Initial results were presented at the Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology in Annapolis, Maryland on August 13, 2016 by Paul Nyirjesy, MD, Professor of Obstetrics and Gynecology and of Medicine at Drexel University College of Medicine.
Clearside Biomedical, Inc. Reports Second Quarter 2016 Financial Results
11 August 2016
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today reported a corporate update and financial results for the quarter ended June 30, 2016 .
ReVision Optics Names Dr. Nick J. Manesis Vice President of R&D
10 August 2016
ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces the appointment of Nick J. Manesis, PhD as Vice President of R&D. Dr. Manesis brings to RVO nearly 30 years of materials research and development experience, including at the leading ophthalmic companies Allergan and CooperVision.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024